Substance · official US FDA label
Naloxone (naloxone)
31 medicines listed on Vimpia contain it, alone or combined. Below, the official US FDA label for naloxone, unchanged.
Want to buy it?
Trouver shows the pharmacies near you that have it right now, and their prices. The reservation pages are in French.
This is a US label.
The official US FDA label for naloxone (published as NALOXONE HYDROCHLORIDE), effective August 25, 2026, describes products sold in the United States. The medicine sold in DR Congo may differ in strength, form or approved uses: ask a pharmacist or a doctor.
Official US FDA label for naloxone
Data provided by the U.S. Food and Drug Administration (openFDA), unchanged. The full label on DailyMed.
Uses
Use(s) to “revive” someone during an overdose from many prescription pain medications or street drugs such as heroin this medicine can save a life
Dosage
US dosage, for products sold in the United States. For a medicine bought in DR Congo, follow its box, its leaflet or your pharmacist.
Directions Step 1: CHECK if you suspect an overdose CHECK for a suspected overdose : the person will not wake up or is very sleepy or not breathing well yell “Wake up!” shake the person gently if the person is not awake, go to Step 2 Step 2: GIVE 1st dose in the nose HOLD the nasal spray device with your thumb on the bottom of the plunger INSERT the nozzle into either NOSTRIL PRESS the plunger firmly to give the 1st dose 1 nasal spray device contains 1 dose Step 3: CALL 911 CALL 911 immediately after giving the 1st dose Step 4: WATCH & GIVE WAIT 2 to 3 minutes after the 1st dose to give the medicine time to work if the person wakes up : Go to Step 5 if the person does not wake up : CONTINUE TO GIVE doses every 2 to 3 minutes until the person wakes up it is safe to keep giving doses Step 5: STAY STAY until ambulance arrives: even if the person wakes up GIVE another dose if the person becomes very sleepy again You may need to give all the doses in the pack 1 check 2 give 3 call step 4 5 stay
Warnings and precautions
Warnings When using this product some people may experience symptoms when they wake up, such as shaking, sweating, nausea, or feeling angry. This is to be expected.
Medicines that contain it
Names as they are sold. A medicine without an English page links to its French page.
- Naloxone (chlorhydrate) 0,4 mg/ml, Injectable
- Naloxone 0,02 mg/ ml, solution injectable
- NALOXONE AGUETTANT 0,4 mg/ml, solution injectable
- Naloxone chlorhydrate 400 mcg/ml, Injectable
- NALOXONE VIATRIS 0,4 mg/1 ml, solution injectable en ampoule
- NYXOID 1,8 mg, solution pour pulvérisation nasale en récipient unidose
- PRENOXAD 0,91 mg/ml, solution injectable en seringue préremplie
- VENTIZOLVE 1,26 mg, solution pour pulvérisation nasale en récipient unidose
- BUPRENORPHINE/NALOXONE ARROW 2 mg/0,5 mg, comprimé sublingual sécable (in French)
Combined with other substances
- BUPRENORPHINE/NALOXONE VIATRIS 2 mg/0,5 mg, comprimé sublingual sécable (in French)
Combined with other substances
- BUPRENORPHINE/NALOXONE VIATRIS 8 mg/2 mg, comprimé sublingual sécable (in French)
Combined with other substances
- Naloxone + Seringue Autobloquant 0,4 mg/ml, Injectable (in French)
Combined with other substances
- OXSYNIA LP 10 mg/5 mg, comprimé à libération prolongée (in French)
Combined with other substances
- OXSYNIA LP 15 mg/7,5 mg, comprimé à libération prolongée (in French)
Combined with other substances
- OXSYNIA LP 2,5 mg/1,25 mg, comprimé à libération prolongée (in French)
Combined with other substances
- OXSYNIA LP 20 mg/10 mg, comprimé à libération prolongée (in French)
Combined with other substances
- OXSYNIA LP 30 mg/15 mg, comprimé à libération prolongée (in French)
Combined with other substances
- OXSYNIA LP 40 mg/20 mg, comprimé à libération prolongée (in French)
Combined with other substances
- OXSYNIA LP 5 mg/2,5 mg, comprimé à libération prolongée (in French)
Combined with other substances
- OXYPRONAL LP 10 mg/5 mg, comprimé sécable à libération prolongée (in French)
Combined with other substances
- OXYPRONAL LP 20 mg/10 mg, comprimé sécable à libération prolongée (in French)
Combined with other substances
- OXYPRONAL LP 30 mg/15 mg, comprimé sécable à libération prolongée (in French)
Combined with other substances
- OXYPRONAL LP 40 mg/20 mg, comprimé sécable à libération prolongée (in French)
Combined with other substances
- OXYPRONAL LP 5 mg/2,5 mg, comprimé à libération prolongée (in French)
Combined with other substances
- SUBOXONE 2 mg/0,5 mg, comprimé sublingual (in French)
Combined with other substances
- SUBOXONE 8 mg/2 mg, comprimé sublingual (in French)
Combined with other substances
- ZUBSOLV 1,4 mg/0,36 mg, comprimé sublingual (in French)
Combined with other substances
- ZUBSOLV 11,4 mg/2,9 mg, comprimé sublingual (in French)
Combined with other substances
- ZUBSOLV 2,9 mg/0,71 mg, comprimé sublingual (in French)
Combined with other substances
- ZUBSOLV 5,7 mg/1,4 mg, comprimé sublingual (in French)
Combined with other substances
- ZUBSOLV 8,6 mg/2,1 mg, comprimé sublingual (in French)
Combined with other substances
Sources
- ●Labels: U.S. Food and Drug Administration, openFDA (public domain). Data provided by the U.S. Food and Drug Administration (openFDA), unchanged. DailyMed.
- ●English names of substances: RxNorm, U.S. National Library of Medicine.
- ●Marketing authorizations: register of the ACOREP, DR Congo.
- ●Essential medicines: national list of essential medicines of DR Congo (LNME).
- ●Composition: public medicines database of France (BDPM), ANSM, open licence.
Public information, for reference only: it does not replace the advice of a pharmacist or a doctor. Vimpia writes nothing about how to use a medicine and translates nothing: the label is the US FDA's, unchanged; names, composition and authorizations come from the official sources above.